Eris Lifesciences domestic formulations offset international remediation drag

Investment View and Valuation

Motilal Oswal Financial Services retains a Neutral rating on Eris Lifesciences. The broker sees domestic branded formulations (DBF) as the principal earnings driver, but believes the current valuation adequately captures the prospective earnings upside. The report highlights slightly better-than-expected revenue in Q1 FY27, although EBITDA and PAT were marginally below estimates.

The broker applies a valuation multiple of 25 times 12-month forward earnings. Its valuation discussion indicates a target-price calculation of approximately Rs 1,450, compared with the stated target of Rs 1,435 and CMP of Rs 1,425.

Q1 FY27 Financial Performance

Eris Lifesciences reported Q1 FY27 revenue growth of 13 per cent year-on-year to Rs 8.7 billion, ahead of Motilal Oswal's estimate of Rs 8.4 billion. DBF revenue increased 14 per cent year-on-year to Rs 8 billion, while international-business revenue grew 5 per cent to Rs 720 million.

Gross margin contracted 350 basis points year-on-year to 72.6 per cent, primarily because of product mix. Solvent-price fluctuations had only a limited impact on gross margin. EBITDA margin declined from the estimated 36.4 per cent to about 33.9 per cent.

Domestic Branded Formulation Growth

The DBF portfolio is heavily weighted towards chronic and sub-chronic therapies, which account for about 85 per cent of revenue and support earnings visibility. Q1 FY27 growth was led by insulin, Onco and Nephro, VMN and GLP-1 therapies.

The two largest therapy areas, oral anti-diabetes and cardiac, represent about 20 per cent and 15.3 per cent of the portfolio, respectively. Eris Lifesciences increased its insulin-market share to 16 per cent in MAT June 2026, while its insulin franchise grew 26.4 per cent in Q1 FY27. The company has not yet entered the insulin-analog market, where five analogue products are scheduled for launch from FY28.

Semaglutide and GLP-1 Opportunity

Management said monthly semaglutide sales have remained stable at about Rs 40 million, with potential upside from an obesity SKU launch in Q2 FY27. Eris Lifesciences' Sundae brand held a 20 per cent market share by sales units and a 21 per cent prescription share in June 2026 in the nascent generic GLP-1 market.

Management, however, noted slower industry semaglutide offtake, patient resistance at clinics across indications and prescriptions being driven mainly by diabetes rather than weight loss, despite successful diabetes-treatment outcomes.

International Business and Regulatory Remediation

The international business remains the key near-term concern. Q1 FY27 international EBITDA fell 19 per cent year-on-year to Rs 180 million, with the margin at about 25 per cent.

Management expects FY27 international revenue to be broadly flat to low-single-digit growth. International EBITDA margin is expected to contract by about 200 basis points because of remediation costs linked to EU regulatory issues. Corrective and preventive action activities are progressing, with sites targeted to be audit-ready by December 2026. Visibility on the full FY27 margin impact is expected after Q2 FY27.

The CDMO base business was resilient because of negligible EU exposure. EU-CDMO pipeline development projects remain on track, and Unit-3 commissioning is targeted.

Estimates and Earnings Outlook

Motilal Oswal reduced its FY27 and FY28 estimates by 6 per cent and 2 per cent, respectively. The revisions reflect assumptions of a gradual recovery in oral anti-diabetes and cardiac therapies and additional Swiss parenterals operating expenditure.

The broker forecasts FY26-28 revenue, EBITDA and PAT CAGRs of 13 per cent, 15 per cent and 28 per cent, respectively, with revenue, EBITDA and PAT expected to reach about Rs 40 billion, Rs 15 billion and Rs 8 billion by FY28.